Among patients with PsA, MetS is associated with certain degenerative changes in the spine and entheses but not with peripheral or axial radiographic damage.

A surge in pollen levels this weekend means the hay fever season is now in full swing — with up to 13 million people set to be affected by debilitating symptoms. Also known as allergic rhinitis ...

Psoriatic arthritis represents a complex interplay between two distinct conditions. For most people, the skin symptoms appear first—typically red, scaly patches known as plaques that can appear ...

Adam also apologised to his followers for having not been "very vocal" about his experience with arthritis lately. He told them in the recent post on Instagram: "[I'm] just struggling and trying ...

Johnson & Johnson announced that the Tremfya (guselkumab) phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

For approximately 85% of patients diagnosed with psoriatic arthritis, the skin manifestations of psoriasis emerge first, with joint symptoms typically developing 7-10 years after initial skin ...

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

for active psoriatic arthritis (PsA). The APEX trial met both its primary and major secondary endpoints at 24 weeks in adults with active PsA. The double-blind, multi-centre trial showed that the ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis. Results from ...